|
Venous thromboembolism (VTE) during or soon after prolonged flight
or travel by motor car has been recorded since 19541 and was labelled
"economy class syndrome" in 1988 (two of the six cases were authors of
that report, and paradoxically, one of the authors with DVT had
travelled in business class).2 Case series have come from
the Paris airports (Orly and Roissy, where the airport emergency
medical service diagnosed PE in 70 incoming passengers during the 24
years to 19983), Heathrow Airport (where
11 of 61 inflight deaths reported to the coroner between 1979 and 1982
were caused by PE4), the island of Martinique
(40 cases of flight-related VTE in six years5) and Réunion island (six
cases in one year6). Lastly, in the Hawaiian
Islands, 17%-25% of patients with VTE admitted to two Honolulu
hospitals had a recent history of air travel.7,8 Others have extended this
association to prolonged travel by bus, car, truck or
train.9
Prolonged travel in a seated position can cause venous stasis, so that
an association of VTE with travel would be consistent with Virchow's
classic postulate that venous stasis contributes to VTE. However,
the present evidence regarding air travel as a cause of VTE is
circumstantial and could be misleading. VTE is a common disorder with
an annual incidence of about one per 1000 population for DVT and 0.5 per
1000 for PE.10 Its incidence is
age-dependent and rises to nearly 1% per annum in the
elderly.11 Given the high community
prevalence of VTE and exponential growth in worldwide air travel by
all age groups, the reports of flight-related VTE from isolated
islands and at busy airports could therefore be mere coincidence.
Clinical suspicion of VTE is notoriously misleading, so that
retrospective reports might be contaminated by diagnostic bias, and
recall bias could influence surveys of predisposing air travel.
Prospective case-control studies seek to minimise bias and estimate
risk by obtaining a history of travel from patients with VTE and also
from contemporary age-matched and sex-matched controls. Two recent
studies from cities with busy international airports have given
opposing results. In Nice, 39 of 160 patients with VTE (24.4%) had
travelled during the previous four weeks (nine by plane, 28 by
motorcar and two by train), compared with 7.5% of 160 age-matched but
not sex-matched controls visiting a cardiology outpatient clinic.
In this study, recent travel raised the odds ratio (OR) for VTE to 4.0
(95% confidence interval, 1.9-8.4; P <
0.0001).12 By contrast, when 788
patients with a clinically suspected DVT were interviewed in
Amsterdam before diagnostic testing, recent travel was no more
prevalent in the 186 patients who had DVT than in the 602 where tests
excluded DVT (the OR for DVT after any recent travel, prolonged
travel, or air travel was 1.0; 95% CI, 0.3-1.4).13 These
case-control studies do not decide the issue, as the control groups
were suboptimal12,13 or the study was too
small to exclude an important effect of prolonged air
travel.13
In the absence of good evidence to the contrary, it is prudent to assume
that air travel can provoke VTE, although the absolute risk remains
uncertain and is probably quite small in most people. This conclusion
derives from the Paris airports emergency medical service
report.3 By relating the number of
people with PE detected during or immediately after a flight to the
total number of arrivals, the report derived an overall incidence of
about one PE per 3 000 000 arriving travellers3 ("true" risk is likely to be
somewhat higher, as about two-thirds of travel-related VTE presents
after patients leave the airport14). The Paris airports
report also observed an obviously greater incidence when travel
times were longer than 12 hours.3 As 10 of the 11 inflight
deaths from PE recorded in the Heathrow report occurred during
prolonged flights,4 it is likely that travel
duration will prove to be important. It is essential that this
still-isolated information is verified and extended with further
studies.
Advice on prevention is based on assumptions about pathogenesis. In
addition to the presumption of venous stasis, there are studies of
aircrew or volunteers during prolonged real or simulated flights
that suggest dehydration,15,16 stress and climatic
change,15 and early activation of
the blood-clotting system17 might also contribute.
Business and first class passengers are not immune, so more generous
seating space is unlikely to be the answer (and "economy class
syndrome" is most likely a misnomer).
The following general advice has no direct supporting evidence but is
common sense, harmless, inexpensive, and likely to be appropriate,
particularly for flights longer than 6-8 hours.18,19 These
general precautions are directed at preventing venous stasis and
include regular foot exercises to activate the plantar and calf
muscle pumps, a generous fluid intake, avoiding excessive alcohol
(especially when combined with the use of hypnotics), and wearing
loose clothing while travelling. Prolonged movement about the cabin
during flight is discouraged because this may bring other hazards,
including from unexpected clear air turbulence.
Travellers with an above-average risk of thrombosis should seek
specific medical advice on additional preventive measures before
travelling. Case series suggest that people with previous VTE,
chronic venous insufficiency, recent surgery, chronic heart and
lung disease, cancer, old age and those who are overweight are all at
greater than average risk. Oral contraceptives, hormone
replacement and inherited thrombophilia (including factor V
Leiden) may predispose, but there is no good published evidence for
this. Screening for factor V Leiden (activated protein C resistance)
is not recommended in this or any other context if there is no personal
or family history of VTE, as about 5% of people of European descent have
this polymorphism, and most will never develop
thrombosis.11
As a generalisation, it usually takes two or three risk factors acting
together to provoke VTE,11 and, as this is likely to
apply also in travellers, it is people with several concurrent risk
factors who are most likely to require specific prophylaxis.
Aspirin alone is not likely to be appropriate, as the evidence that
aspirin prevents DVT or PE is highly controversial and the plausible
level of risk reduction is small.20,21 Prescribing aspirin
for all travellers may also cause sufficient excess bleeding to
negate any benefit. Graded pressure support stockings to be worn
during flight must be carefully fitted: too tight and they become a
tourniquet, too loose and they are ineffective. And they are
contraindicated in some people with advanced peripheral vascular
disease. People at highest risk (including those with previous VTE)
should consider self-injecting a low molecular weight heparin
before and perhaps for some days after travel.
Few people die of PE without some warning from unexpected
breathlessness, chest pain, or leg symptoms. Information kits about
DVT and PE, predisposing factors and various clinical presentations
should therefore be widely distributed to travellers before they
leave home. People should know that, although symptoms of VTE may
arise during flight, they are more often first noticed some time after
landing. More importantly, we need better evidence. If the present
media crisis and federal inquiry brings a greater awareness that VTE
may develop during or soon after prolonged travel, and if it triggers a
productive collaboration of airlines with investigators to measure
the real risk and evaluate preventive measures, then it will have
served a useful purpose.
Alex S Gallus
Professor of Haematology and Director of Pathology Services
Flinders Medical Centre and Repatriation General Hospital
Adelaide, SA
Ross I Baker
Director, Thrombosis and Haemophilia Service, Royal Perth Hospital
and
Clinical Senior Lecturer in Medicine, University of Western
Australia
Perth, WA
- Homans J. Thrombosis of the deep leg veins due to prolonged sitting.
N Engl J Med 1954; 250: 148-149.
-
Cruikshank JM, Gorlin J, Jennett B. Air travel and thrombotic
episodes: the economy class syndrome. Lancet 1988; 2:
497-498.
-
Clerel M, Caillard G. Thromboembolic syndrome from prolonged
sitting and flights of long duration: experience of the Emergency
Medical Service of the Paris Airports. Bull Acad Natl Med
1999; 183: 985-997.
-
Sarvesvaran R. Sudden natural deaths associated with commercial
air travel. Med Sci Law 1986; 26: 35-38.
-
Ribier G, Zizka V, Cysique J, et al. Venous thromboembolic
complications following air travel. Retrospective study of 40 cases
recorded in Martinique. Rev Med Interne 1997; 18: 601-604.
-
Paganin F, Laurent Y, Gaüzere BA, et al. Pulmonary embolism on
non-stop flights between France and Reunion Island [letter].
Lancet 1996; 347: 1195-1196.
-
Eklof B, Kistner RL, Masuda EM, et al. Venous thromboembolism in
association with prolonged air travel. Dermatol Surg 1996;
22: 637-641.
-
Mercer A, Brown JD. Venous thromboembolism associated with air
travel. Aviat Space Environ Med 1998; 69: 154-157.
-
Tardy B, Page Y, Zeni F, et al. Phlebitis following travel.
Presse Medicale 1993; 22: 811-814.
-
Van Beek ER, BŸller HR, ten Cate JW. Epidemiology of venous
thromboembolism. In: Tooke JE, Lowe GDO, editors. A textbook of
vascular medicine. London: Arnold, 1996: 471-488.
-
Rosendaal FR. Venous thrombosis: a multicausal disease.
Lancet 1999; 353: 1167-1173.
-
Ferrari E, Chevallier T, Chapelier A, Baudouy M. Travel as a risk
factor for venous thromboembolic disease: a case-control study.
Chest 1999; 115: 440-444.
-
Kraaijenhagen RA, Haverkamp D, Koopman MMW, et al. Travel and risk
of venous thrombosis. Lancet 2000; 356: 1492-1493.
-
Bounameaux H. Thromboembolism and air travel [letter].
Lancet 1988; 2: 797.
-
Carruthers M, Arguelles AE, Mosovich A. Man in transit:
biochemical and physiological changes during intercontinental
flights. Lancet 1976; 1: 977-981.
-
Simons R, Krol R. Jet lag, pulmonary embolism, and hypoxia.
Lancet 1996; 348: 416.
-
Bendz B, Rostrup M, Sevre K, et al. Association between acute
hypobaric hypoxia and activation of coagulation in human beings.
Lancet 2000; 356: 1657-1658.
-
Kesteven PL. Traveller's thrombosis. Thorax 2000; 55
(Suppl 1): S32-S36.
-
Ferriman A. Travellers should be warned of thrombosis risk.
BMJ 2000; 321: 1310.
-
Sors H, Meyer G. Place of aspirin in prophylaxis of venous
thromboembolism. Lancet 2000; 355: 1288-1289.
-
Cohen A, Quinlan D. PEP trial [letter]. Lancet 2000; 356:
247.
©MJA 2001
Make a
comment
Readers may print a single copy for personal use. No further
reproduction or distribution of the articles
should proceed without the permission of the publisher. For
permission, contact the
Australasian Medical Publishing Company.
Journalists are welcome to write news stories based on what they read here, but should acknowledge their source as "an article published on the Internet by The Medical Journal of Australia <http://www.mja.com.au>".
<URL: http://www.mja.com.au/>
© 2001 Medical Journal of Australia.
|